Figures
In Figs 2, 3, and 4, a trial named “Onofrj, 1995” should not be included. Please see the corrected figures here.
Patients receiving ALC showed significantly more reduction in VAS scores than those receiving placebo. The values presented referred to the change of VAS scores from baseline. VAS = Visual Analogue Scale; ALC = acetyl-l-carnitine; UCE = U.S.-CanadianEuropean Study; UC = U.S.-Canadian Study; SD = standard deviation; CI = confidence interval.
Subgroup-analysis was performed by subdividing RCTs according to whether the peripheral neuropathy diagnosed in patients was diabetic or non-diabetic. Taking ALC decreased VAS scores significantly in diabetic patients. VAS = Visual Analogue Scale; ALC = acetyl-l-carnitine; UCE = U.S.-Canadian-European Study; UC = U.S.-Canadian Study; SD = standard deviation; CI = confidence interval.
Oral administration of ALC decreased VAS scores significantly. VAS = Visual Analogue Scale; ALC = acetyl-l-carnitine; UCE = U.S.-Canadian-European Study; UC = U.S.-Canadian Study; SD = standard deviation; CI = confidence interval.
Reference
Citation: Li S, Li Q, Li Y, Li L, Tian H, Sun X (2015) Correction: Acetyl-L-carnitine in the Treatment of Peripheral Neuropathic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials. PLoS ONE 10(6): e0129991. https://doi.org/10.1371/journal.pone.0129991
Published: June 12, 2015
Copyright: © 2015 Wynd et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited